HOTH - Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

Hoth Therapeutics (HOTH) intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases in U.S.HT-KIT targets a shared cell signaling pathway that may have therapeutic potential for multiple rare cancers, including:Aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemiaAcute myeloid leukemiaGastrointestinal stromal tumors Drugs intended to treat orphan diseases are eligible to apply for Orphan Drug Designation, which provides multiple benefits to the sponsor during development and after approval.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, tax credits and Waiver of NDA/BLA application fee, if approved.HOTH shares rise 10% premarket trading at $1.66. Recently, Hoth announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for mast cell-derived cancers.

For further details see:

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers